3-methyl-1-(2-(1-methyl-1H-indol-5-ylamino)pyrimidin-4-yl)-1H-pyrazole-4-carbaldehyde | 1448307-71-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-methyl-1-(2-(1-methyl-1H-indol-5-ylamino)pyrimidin-4-yl)-1H-pyrazole-4-carbaldehyde
• 英文别名: 3-methyl-1-[2-[(1-methylindol-5-yl)amino]pyrimidin-4-yl]pyrazole-4-carbaldehyde
• CAS: 1448307-71-8
• 化学式: C₁₈H₁₆N₆O
• 分子量: 332.365
• InChiKey: PAHARIHYTQTTSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  77.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  氮杂环丁烷-3-醇 、 3-methyl-1-(2-(1-methyl-1H-indol-5-ylamino)pyrimidin-4-yl)-1H-pyrazole-4-carbaldehyde 在 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-((3-methyl-1-(2-(1-methyl-1H-indol-5-ylamino)pyrimidin-4-yl)-1H-pyrazol-4-yl)methyl)azetidin-3-ol
  参考文献：
  名称：

  Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors

  摘要：

  A series of pyrazolylpyrimidine scaffold based Syk inhibitors were synthesized and evaluated for their biological activities and selectivity. Lead optimization efforts provided compounds with potent Syk inhibition in both enzymatic and TNF-a release assay. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.011
• 作为产物：
  描述：

  (3-methyl-1-(2-(1-methyl-1H-indol-5-ylamino)pyrimidin-4-yl)-1H-pyrazol-4-yl)methanol 在 二氧化锰 二氯甲烷 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以to give desired intermediate 8 as a pale yellow solid (0.77 g, 36%)的产率得到3-methyl-1-(2-(1-methyl-1H-indol-5-ylamino)pyrimidin-4-yl)-1H-pyrazole-4-carbaldehyde
  参考文献：
  名称：

  Substituted pyrimidine compounds and their use as SYK inhibitors

  摘要：

  公开了化学式（I）的化合物及抑制激酶（包括脾酪氨酸激酶）的方法。还公开了通过向受试者投予化学式（I）的化合物的治疗有效量来治疗激酶介导疾病或疾病状态的方法。

  公开号：

  US08871778B2

文献信息

• [EN] SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS<br/>[FR] COMPOSÉS DE TYPE PYRIMIDINE SUBSTITUÉE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DES KINASES SYK
  申请人：GENOSCO

  公开号：WO2013109882A1

  公开（公告）日：2013-07-25

  Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

  公式（I）的化合物和抑制激酶的方法被揭示。还揭示了通过向受试者投予公式（I）的化合物的治疗有效量来治疗激酶介导的疾病或病况的方法。
• SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS
  申请人：OSCOTEC, INC.

  公开号：US20130274242A1

  公开（公告）日：2013-10-17

  Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

  本文披露了化学式(I)的化合物及其抑制酶，包括脾酪氨酸激酶的方法。同时还披露了通过向受试者施用化学式(I)化合物的治疗有效剂量来治疗酶介导的疾病或状况的方法。
• US8871778B2
  申请人：——

  公开号：US8871778B2

  公开（公告）日：2014-10-28
• Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors
  作者：Jang-Sik Choi、Hae-jun Hwang、Se-Won Kim、Byung Il Lee、Jaekyoo Lee、Ho-Juhn Song、Jong Sung Koh、Jung-Ho Kim、Phil Ho Lee

  DOI：10.1016/j.bmcl.2015.09.011

  日期：2015.10

  A series of pyrazolylpyrimidine scaffold based Syk inhibitors were synthesized and evaluated for their biological activities and selectivity. Lead optimization efforts provided compounds with potent Syk inhibition in both enzymatic and TNF-a release assay. (C) 2015 Elsevier Ltd. All rights reserved.
• Substituted pyrimidine compounds and their use as SYK inhibitors
  申请人：Genosco

  公开号：US08871778B2

  公开（公告）日：2014-10-28

  Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

  公开了化学式（I）的化合物及抑制激酶（包括脾酪氨酸激酶）的方法。还公开了通过向受试者投予化学式（I）的化合物的治疗有效量来治疗激酶介导疾病或疾病状态的方法。